
J&J’s Baby powder tested in India and Bangladesh
pharmafile | December 21, 2018 | News story | Medical Communications | Bangladesh, Cancer, India, J&J, JJ, asbestos
Bangladeshi authorities will collect and test samples of Johnson & Johnson’s baby powders for traces of cancer causing asbestos, after a Reuter’s report revealed that the company had known it’s product had tested positive for asbestos since at least 1971.
The news comes after Indian regulators ordered J&J to stop manufacturing its Baby Powder using raw materials, in two of its Indian factories, until tests prove that the products are free of the carcinogenic contaminant.
We take this issue seriously and within a couple of days we will collect samples from the market,” S.M. Isahaque Ali, a director at the Bangladesh Standards and Testing Institution (BSTI), told Reuters.
J&J deny allegations and have described Reuters’ investigation as “one-sided, false and inflammatory”.
The company added that “All talc in India is sourced and exclusively sold in India and surrounding markets – including Sri Lanka, Bangladesh, Nepal, Bhutan, Maldives – and fully meets the regulatory standards of the Government of India.”
Louis Goss
Related Content

Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds

BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …

T-cell therapy – the evolution of cancer treatments
The current forms of immunotherapy, how T cell therapy works and what the future holds






